Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

We examined effects of carfilzomib-dexamethasone (Kd56) versus bortezomib-dexamethasone (Vd) on health-related quality of life (HR-QoL) in relapsed/refractory multiple myeloma (MM) patients from the ENDEAVOR study. HR-QoL was assessed by the European Organisation for Research and Treatment of Cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludwig, Heinz, Moreau, Philippe, Dimopoulos, Meletios A., Mateos, Maria-Victoria, Kaiser, Martin, Hajek, Roman, Feng, Shibao, Cocks, Kim, Buchanan, Jaqueline, Weisel, Katja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386751/
https://www.ncbi.nlm.nih.gov/pubmed/30796199
http://dx.doi.org/10.1038/s41408-019-0181-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386751/
https://www.ncbi.nlm.nih.gov/pubmed/30796199
http://dx.doi.org/10.1038/s41408-019-0181-0

Ejemplares similares